1.A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer.
Jong Soo CHOI ; Kyoo Hyung LEE ; Myung Ju AHN ; Jung Shin LEE ; Je Han LEE ; Dae Young ZANG ; Chel Won SUH ; Sang We KIM ; Woo Gun KIM ; Jin Cheon KIM ; SukKoo KIM ; Kun Choon PARK ; Moo Song LEE ; Sang Hee KIM
The Korean Journal of Internal Medicine 1997;12(2):155-162
OBJECTIVES: To determine the effectiveness and toxicity when levamisole was added to the adjuvant combination chemotherapy in patients with operable gastric cancer. METHODS: After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992, 100 patients were randomized to 6 months of 5-fluorouracil 1,000 mg/m2/day administered as continuous infusion for 5 days, cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole (50 mg every eight hours P.O for a period of three days every 2 weeks for 6 months). This chemotherapy treatment was begun within 2 to 4 weeks after the surgery. The chemotherapy consisted of discrete 5-day courses administered at 4-weeks intervals. All 100 patients are assessable. RESULTS: The fifty patients were assigned to each treatment group. There was no statistical difference and no bias in the distribution of characteristics of the 100 evaluable patients between the two groups. A total of 274 courses of treatment were given in the levamisole group and 260 courses of treatment in non-levamisole group. Eleven patients in each group did not finish planned 6 courses of treatment mainly due to non-compliance. At median follow up of 39 months, 32 patients relapsed 19 in the levamisole group and 13 in the non-levamisole group (p = 0.284). Twenty five patients died of relapsed diseases, 15 in the levamisole group and 10 in the non-levamisole group. The levamisole group tended to show more risk of overall death rate and recurrence than the non-levamisole group. However, this result was not statistically significant at 3 years. The treatment was well tolerated in both treatment groups. The grade 2-3 toxicities were nausea/ vomiting (levamisole, non-levamisole group; 31.7%, 29.3% of treatment courses respectively), diarrhea (7.6%, 8.4%), mucositis (11.6%, 12.3%), and leukopenia (9.8%, 9.6%). CONCLUSION: Levamisole had negative effects on disease-free survival and overall survival when added to adjuvant combination chemotherapy of cisplatin and 5-fluorouracil in patients with operable gastric cancer. Both treatment arms were generally well tolerated and the toxicity profile was similar with or without levamisole.
Adjuvants, Immunologic/administration & dosage*
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use*
;
Antineoplastic Agents, Combined/adverse effects
;
Cisplatin/administration & dosage
;
Comparative Study
;
Female
;
Fluorouracil/administration & dosage
;
Human
;
Levamisole/administration & dosage*
;
Male
;
Middle Age
;
Stomach Neoplasms/mortality
;
Stomach Neoplasms/drug therapy*
2.Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
Jung Hee LEE ; Je Hwan LEE ; Tae Won KIM ; Kyoo Hyung LEE ; Yoon Koo KANG ; Jung Shin LEE ; Sang Hee KIM ; Hee Cheol KIM ; Chang Sik YU ; Jin Cheon KIM ; Woo Kun KIM
Journal of Korean Medical Science 2001;16(1):69-74
There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment. The present study was designed to assess the efficacy and toxicities of a combination of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in fluoropyrimidine-pretreated patients with metastatic colorectal cancer. Chemotherapy consisted of oxaliplatin 85 mg/m2 on day 1, followed by leucovorin 20 mg/m2 and 5-FU 1,200 mg/m2 on days 1 and 2. Treatment courses were repeated every two weeks. Thirty-nine patients were enrolled in this study. All patients previously received fluoropyrimidine-based chemotherapy. Thirty-one patients were assessable for response and 33 for treatment toxicity. Six patients required dose reduction of 5-FU due to grade III/IV cytopenia. Nausea/vomiting and peripheral neuropathy were common non-hematologic toxicities. Overall response rate was 42.0% including 3 complete response and 10 partial response. The median response duration was 91 days (range, 28-224+). The median duration of progression-free survival was 132 days (range, 40-308). A combination of oxaliplatin, 5-FU, and leucovorin showed high response rate in fluoropyrimidine-pretreated patients with metastatic colorectal cancer, but the duration of response was relatively short. It may be worthwhile to explore its therapeutic potential in the first-line treatment setting.
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use*
;
Antineoplastic Agents, Combined/adverse effects
;
Colorectal Neoplasms/mortality
;
Colorectal Neoplasms/drug therapy*
;
Disease-Free Survival
;
Female
;
Fluorouracil/administration & dosage
;
Human
;
Leucovorin/administration & dosage
;
Male
;
Middle Age
;
Organoplatinum Compounds/administration & dosage
3.Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
Yihebali CHI ; Jian-Hong REN ; Lin YANG ; Cheng-Xu CUI ; Jun-Ling LI ; Jin-Wan WANG
Chinese Medical Journal 2011;124(19):2997-3002
BACKGROUNDA phase III trial involving docetaxel, cisplatin, and fluorouracil (DCF) in the treatment of advanced gastric cancer was shown to have superior efficacy compared to cisplatin and fluorouracil alone, but with a high rate of hematologic toxicity. To reduce toxicity while maintaining the efficacy of DCF, we reduced the doses of docetaxel (D) and cis-platinum (CDDP), and administered 5-fluorouracil (5-FU) via a continuous intravenous (CIV) infusion.
METHODSChemotherapy-naive patients with gastric adenocarcinomas received D (60 mg/m(2) 1 hour on day 1), CDDP (30 mg/m(2) on days 1 and 2), and 5-FU (1500 mg×m(-2)×24 h(-1) CIV on days 1 and 8 every 3 weeks). The primary endpoint was the response rate.
RESULTSFourteen patients were enrolled. Based on the efficacy evaluation following at least 2 cycles of treatment, there was 7.1% complete remission (CR), 71% partial remission (PR), 14% stable disease (NC/SD), and 7.1% progressive disease (PD). The median survival time was 13 months. Nine patients (64%) had grade III-IV neutropenia, and 4 patients (29%) had grade IV neutropenia, among whom 1 had grade IV neutropenia with grade III nausea and vomiting.
CONCLUSIONThe modified DCF regimen is highly active and has a favorable toxicity profile in Chinese patients with gastric cancer.
Adenocarcinoma ; drug therapy ; Antimetabolites, Antineoplastic ; administration & dosage ; Antineoplastic Agents ; administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cisplatin ; administration & dosage ; Female ; Fluorouracil ; administration & dosage ; Humans ; Male ; Middle Aged ; Stomach Neoplasms ; drug therapy ; Taxoids ; administration & dosage
4.Clinical Result of Prolonged Primary Chemotherapy in Retinoblastoma Patients.
Jeong Hun KIM ; Young Suk YU ; Sang In KHWARG ; Hyoung Soo CHOI ; Hee Young SHIN ; Hyo Seop AHN
Korean Journal of Ophthalmology 2003;17(1):35-43
This study evaluated the effects of prolonged primary chemotherapy in retinoblastoma. The data for 27 eyes in 22 children who were treated for retinoblastoma with up to 13 cycles of primary chemotherapy was reviewed. The chemotherapy consisted of etoposide, vincristine, and either carboplatin or ifosfamide. In bilateral retinoblastoma, 1 eye was in each Ia, Ib, and Va, according to the Reese-Ellsworth classification, 2 in each IIa, IIIa, and IIIb, 4 in IIb, and 5 in IVa. Enucleation was performed in 1 in IIa and 1 in Va. In unilateral, 1 was in each IIa, IIIa, IVa, IVb, and Vb, and 4 in Va. Enucleation was performed in 8 with the exception of 1 in IIa. Complete regression was observed in 17 eyes (12 patients). There was no toxicity severe enough to delay treatment. Prolonged primary chemotherapy can be considered as an alternative treatment for retinoblastoma in III or less.
Antineoplastic Agents/administration& dosage
;
Antineoplastic Agents, Alkylating/administration& dosage
;
Antineoplastic Agents, Phytogenic/administration& dosage
;
Antineoplastic Combined Chemotherapy Protocols/*administration& dosage
;
Carboplatin/administration& dosage
;
Child, Preschool
;
Drug Administration Schedule
;
Etoposide/administration& dosage
;
Eye Enucleation
;
Human
;
Ifosfamide/administration& dosage
;
Infant
;
Retinal Neoplasms/*drug therapy/surgery/ultrasonography
;
Retinoblastoma/*drug therapy/surgery/ultrasonography
;
Retrospective Studies
;
Vincristine/administration& dosage
5.Research progress of the anti-tumor effect of sonodynamic and photodynamic therapy.
Xiaomin SU ; Long LI ; Pan WANG
Journal of Biomedical Engineering 2012;29(3):583-587
Cancer, as a serious threat to human health, is one of the major killers. The treatment of cancer has attracted more and more attention. Currently, the means of treating cancer is also increasing, but there is no emergence of a fully satisfactory treatment. A combination of sonodynamic therapy (SDT) and photodynamic therapy (PDT), named sono-photodynamic therapy (S-PDT), is a new composite cancer therapy. Because the therapy can significantly improve the tumor curing effect, it has good application prospects in cancer prevention and treatment. The present article reviewed the progress of the anti-tumor mechanisms and influencing factors of S-PDT.
Animals
;
Antineoplastic Agents
;
administration & dosage
;
Combined Modality Therapy
;
Hematoporphyrin Derivative
;
administration & dosage
;
Hematoporphyrin Photoradiation
;
Humans
;
Neoplasms
;
drug therapy
;
therapy
;
Photochemotherapy
;
methods
;
Photosensitizing Agents
;
administration & dosage
;
Ultrasonic Therapy
;
methods
6.Short-term therapeutic effect of Endostar combined with chemotherapy for advanced colorectal cancer: a meta-analysis.
Journal of Southern Medical University 2014;34(2):270-274
OBJECTIVETo evaluate the safety and efficacy of Endostar combined with chemotherapy in the treatment of end-stage colorectal cancer.
METHODSs The relevant randomized controlled trials were retrieved from the electronic databases of Cochrane library, PubMed, EMbase, CNKI, CBM, VIP and Chinese Medical Association. The retrieval time limit was from the database construction to January 2013. The data were extracted from eligible studies assessed for methodological quality according to Cochrane handbook for systematic reviews and analyzed using RevMan 5.2 software.
RESULTSFive randomized controlled trials involving 220 cases were included for meta-analysis. The results showed that Endostar combined with chemotherapy had an overall advantage over chemotherapy alone in terms of complete response rate (10.91% vs 2.73% RR=4.08, 95% CI: 1.19-13.95, P=0.02), partial response rate (48.18% vs 30.91% RR=2.18, 95% CI: 1.23-3.87, P=0.007), progressive disease (15.45% vs 41.82% RR=0.25, 95% CI: 0.13-0.47, P<0.0001), and the response rate (60.00% vs 33.64% RR=3.23, 95% CI: 1.79-5.81, P<0.0001). Clinical benefit response(82.73% vs 55.45% RR=4.30,95% CI:1.19-13.95, P<0.0001). The main adverse reactions included nausea, vomiting, constipation, palpitation, and electrocardiogram changes.
CONCLUSIONEndostar combined with chemotherapy is effective for advanced colorectal cancer and can be used as a routine treatment.
Antineoplastic Agents ; administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Colorectal Neoplasms ; drug therapy ; Endostatins ; administration & dosage ; Humans ; Randomized Controlled Trials as Topic
7.Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide.
The Korean Journal of Internal Medicine 2013;28(3):377-379
No abstract available.
Antineoplastic Agents/administration & dosage
;
*Antineoplastic Combined Chemotherapy Protocols
;
Clarithromycin/administration & dosage
;
Cyclophosphamide/administration & dosage
;
Humans
;
Lymphoma, Follicular/*drug therapy
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/*drug therapy
;
Prednisolone/administration & dosage
;
Protein Synthesis Inhibitors/administration & dosage
8.Which treatment modality should we choose for advanced hepatocellular carcinoma?.
The Korean Journal of Hepatology 2010;16(4):353-354
No abstract available.
Adult
;
Aged
;
Antineoplastic Agents/administration & dosage
;
Antineoplastic Combined Chemotherapy Protocols
;
Benzenesulfonates/administration & dosage
;
Carcinoma, Hepatocellular/mortality/*therapy
;
Chemoembolization, Therapeutic
;
Cisplatin/administration & dosage
;
Fluorouracil/administration & dosage
;
Humans
;
Infusions, Intra-Arterial
;
Liver Neoplasms/mortality/*therapy
;
Middle Aged
;
Pyridines/administration & dosage
;
Survival Rate
9.Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma.
Li-Xia WANG ; Hua LU ; Wen-Yi SHEN ; Si-Xuan QIAN ; Hong-Xia QIU ; Han-Xin WU ; Jian-Fu ZHANG ; Yu-Jie WU ; Jian-Yong LI
Journal of Experimental Hematology 2008;16(4):943-945
The objective of study was to evaluate the efficiency and safety of bortezomib for the treatment of multiple myeloma. Bortezomib in combination with dexamethasone was administered as first-line treatment in all 7 newly diagnosed patients with multiple myeloma. The patients with refractory myeloma were treated with bortezomib in combination with dexamethasone or with other traditional agents such as mitoxantrone and thalidomide. The results showed that according to the EMBT criteria, out of 7 patients one achieved complete response (CR), five achived partial response (PR) and one achived minor response (MR). The 3 patients with refractory/relapsed myeloma achieved PR (2/3) and MR (1/3). The overall response rate (CR + PR) was 80%. The most frequent adverse events observed were thrombocytopenia in three patients, diarrhea and peripheral neuropathy in one respectively. In conclusion, bortezomib demonstrates efficiency in the treatment of new-diagnosed and refractory/relapsed multiple myeloma, and the side effects from treatment are acceptable and manageable.
Adult
;
Aged
;
Antineoplastic Agents
;
administration & dosage
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Boronic Acids
;
administration & dosage
;
Bortezomib
;
Dexamethasone
;
administration & dosage
;
Female
;
Humans
;
Male
;
Middle Aged
;
Multiple Myeloma
;
drug therapy
;
Protease Inhibitors
;
administration & dosage
;
Pyrazines
;
administration & dosage
10.Visual Prognosis of Retinoblastoma in the Posterior Pole Treated with Primary Chemotherapy Plus Local Treatments.
Jae Min KIM ; Jeong Hun KIM ; Seong Joon KIM ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN ; Young Suk YU
Korean Journal of Ophthalmology 2010;24(6):347-352
PURPOSE: To evaluate the visual outcomes of retinoblastoma in the posterior pole (RBPP) treated with chemotherapy plus local treatments and to address the prognostic factors that influence such outcomes. METHODS: The medical records of patients with RBPP diagnosed at the Department of Pediatric Ophthalmology, Seoul National University Children's Hospital between August 1987 and September 2007 were reviewed retrospectively. Only those patients treated via primary chemotherapy plus local treatments were included. The presence of foveal involvement and tumors in the posterior pole before and after treatment, the type of regression pattern and the best corrected visual acuity (BCVA) of each patient were evaluated. RESULTS: A total of 13 eyes in 12 patients were included. The mean final BCVA for treated RBPP was 20/210 (range, hand motion to 20/16). However, eight eyes (61.5%) had an acuity of 20/200 or better and seven eyes (53.8%) had an acuity of 20/50 or better. The mean final BCVA was significantly better in cases with negative foveal involvement; however, four eyes (37.5%) with positive foveal involvement had an acuity of 20/200 or better. Tumors area in the posterior pole and the type of regression pattern were not significantly related to final BCVA. CONCLUSIONS: Over one half of the studied RBPP patients had working vision. Although the eyes had RBPP with positive foveal involvement, about one-third of the patients had working vision. Vision preservation should be considered when deciding on RBPP treatment.
Antibiotics, Antineoplastic/administration & dosage
;
Antineoplastic Agents/administration & dosage
;
Antineoplastic Agents, Alkylating/administration & dosage
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Cisplatin/administration & dosage
;
Cyclophosphamide/administration & dosage
;
Doxorubicin/administration & dosage
;
Etoposide/administration & dosage
;
Eyeglasses
;
Female
;
Follow-Up Studies
;
Fovea Centralis/pathology
;
Humans
;
Infant
;
Male
;
Prognosis
;
Retinal Neoplasms/*drug therapy/pathology/*physiopathology
;
Retinoblastoma/*drug therapy/pathology/*physiopathology
;
Retrospective Studies
;
Treatment Outcome
;
Visual Acuity